li Lilly has paid Oxford-based Sitryx $50 million (€46 million) upfront for global rights to up to four autoimmune drugs. The deal sees Lilly commit to up to $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.

Sitryx is focused on the regulation of cell metabolism. By targeting such pathways, the British biotech thinks it can advance disease-modifying immuno-oncology and immuno-inflammation therapies. The potential of the idea, and credentials of the immunology and metabolism researchers who founded the company, enabled Sitryx to raise $30 million from backers including GlaxoSmithKline in 2018. Source: Fierce Biotech. 30/3/2020